Biotricity Reports Financial Results for Fiscal 2023 First Quarter
Biotricity Reports Financial Results for Fiscal 2023 First Quarter
REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.
加利福尼亞州雷德伍德城/ACCESSWIRE/2022年8月15日/醫療診斷和消費者保健技術公司Biotricity Inc.(納斯達克代碼：BTCY)(以下簡稱“公司”)今天公佈了截至2022年6月30日的2023財年第一季度財務業績。
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks."
Biotricity創始人兼首席執行官Waqaas Al-Siddiq博士表示：“隨着我們開始通過我們已建立的網絡推出新的Biotres和BioHeart產品線，我們對收入的同比增長和毛利率保持在60%的能力感到高興。這兩個新產品將補充我們通過BioFlux建立的現有平臺，使Biotricity生態系統成為心臟病專家的一站式解決方案。此外，由於Biotres是一種與Bioflow相比容量更大的無線可穿戴心臟監測設備，我們預計將擴大我們的分銷範圍，包括醫院網絡或集成交付網絡等渠道。”
Q1-FY23 Financial Highlights:
第一季度至23財年財務亮點：
- Revenue totaled $2.1 million.
- Gross profit totaled $1.2 million.
- Gross profit margins were 60% and consistent with the full year FY22.
- Net loss totaled $5 million or $0.098 per share; adjusted loss per share, a non- GAAP measure, was $0.085 per share after removing certain non-recurring expenses.
- 總收入為210萬美元。
- 毛利潤總計120萬美元。
- 毛利率為60%，與22財年全年持平。
- 淨虧損總計500萬美元，或每股0.098美元；調整後的每股虧損(非公認會計準則衡量標準)在扣除某些非經常性費用後為每股0.085美元。
Operating Highlights for the FY22 to Date:
到目前為止，22財年的運營要點：
- After receiving FDA 510(k) clearance in January 2022, in April 2022, Biotricity officially launched wireless wearable holter patch device, Biotres, a revolutionary holter technology.
- Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem.
- Launched Bioheart, one of the first heart rhythm recorders and personal heart lifestyle solutions.
- Expanded our network to cover 29 states with over 2,000 physicians using our product.
- 在2022年1月獲得FDA 510(K)批准後，2022年4月，Biotricity正式推出了無線可穿戴Holter貼片設備Biotres，這是一項革命性的Holter技術。
- 推出了Biokit，這是一款集成到Biotricity生態系統中的個人醫療設備套件。
- 推出了首批心臟節律記錄儀和個人心臟生活方式解決方案之一BioHeart。
- 將我們的網絡擴展到29個州，有超過2,000名醫生使用我們的產品。
Full details of the Company's financial results will be filed with the SEC on Form 10-Q by visiting www.sec.gov.
公司財務業績的全部細節將以10-Q表格的形式提交給美國證券交易委員會，網址為www.sec.gov。
Financial Results Conference Call
財務業績電話會議
Management will host a conference call on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter and provide a business update. Additional details are available under the Investor Relations section of the Company's website:
管理層將於2022年8月15日(星期一)下午4：30主持電話會議。ET討論其2023財年第一季度的財務業績，並提供業務最新情況。欲瞭解更多詳情，請登錄公司網站投資者關係欄目：
Event: |
Biotricity Fiscal First Quarter 2023 Financial Results Conference Call |
Date: |
Monday, August 15, 2022 |
Time: |
4:30 p.m. Eastern Time |
Live Call: |
1-888-220-8451 (U.S. Toll-Free) or 1-646-828-8193 (International) |
Webcast: |
活動： |
Biotricity財年2023年第一季度財務業績電話會議 |
日期： |
2022年8月15日(星期一) |
時間： |
下午4：30東部時間 |
現場通話： |
1-888-220-8451(美國免費)或1-646-828-8193(國際) |
網絡直播： |
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 29, 2022 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 2688378.
對於不能參加電話會議的感興趣的個人，在2022年8月29日之前可以撥入電話重播，可以通過撥打+1-844-512-2921(美國免費)或+1-412-317-6671(國際)並輸入重播密碼：2688378來收聽。
About Biotricity:
關於Biotricity公司：
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit .
Biotricity正在通過彌合遠程監測和慢性護理管理方面的差距來改革醫療保健市場。醫生和患者信賴Biotricity無與倫比的預防和個人護理標準，包括針對慢性病的診斷和診斷後解決方案。該公司為醫療和消費市場開發全面的遠程健康監測解決方案。要了解更多信息，請訪問。
Important Cautions Regarding Forward Looking Statements:
有關前瞻性陳述的重要警告：
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
本新聞稿中包含的任何不描述歷史事實的陳述都可能構成前瞻性陳述。前瞻性陳述涉及假設並描述我們未來的計劃、戰略和預期，通常可以通過使用“可能”、“應該”、“將”、“將”、“可能”、“預定”、“預期”、“預期”、“估計”、“相信”、“打算”、“尋求”、“項目”或“目標”或這些詞語或類似術語的其他變體來識別。前瞻性陳述可能包括但不限於：(I)未來經營的計劃、目標和目標，包括與BioFlux或公司任何其他擬議產品或服務的設計、開發和商業化有關的計劃、目標或目標；(Ii)收入(包括收益/虧損)、每股收益(包括收益/虧損)、資本支出、股息、資本結構或其他財務項目的預測；(Iii)公司未來的財務業績，(Iv)本公司營運或擬營運的監管制度及(V)上文第(I)、(Ii)、(Iii)或(Iv)點所述任何陳述所依據或有關的假設。此類前瞻性陳述不是為了預測或保證實際結果、業績、事件或情況，也可能無法實現，因為它們是基於公司目前的預測、計劃、目標、信念、預期、估計和假設，受到許多風險、不確定因素和其他影響的影響, 其中許多是公司無法控制的。由於這些風險和不確定性，某些事件和情況的實際結果和時間可能與前瞻性陳述中描述的大不相同。可能影響或導致前瞻性陳述不準確或導致實際結果與預期或預期結果大不相同的因素可能包括但不限於，公司無法獲得額外融資，與其產品開發相關的大量時間和資源，以及相關的現金流不足和導致的流動性不足，公司無法擴大公司業務，政府對醫療器械和保健行業的重大監管，產品缺乏多樣性，現有或加劇的競爭，仲裁和訴訟的結果，股票波動和流動性不足，以及公司未能執行公司的業務計劃或戰略。這些因素和其他因素在該公司提交給美國證券交易委員會的文件中得到了更詳細的識別和描述。不能保證該公司將永遠盈利。公司沒有義務更新任何前瞻性陳述，以反映本新聞稿發佈之日之後可能發生的任何事件或情況。
Use of Non-GAAP Information
非公認會計原則信息的使用
In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP in this press release, Biotricity presents adjusted net loss, which is a non-GAAP financial measure. Adjusted net loss is determined by deducting one-time derivative fair value and accretion expenses from net loss attributable to common shareholders. Our definition of adjusted net loss may not be comparable to the definitions of similarly titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of its reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management.
除了根據公認會計原則或本新聞稿中的GAAP公佈的未經審計的結果外，Biotricity還公佈了調整後的淨虧損，這是一種非GAAP財務衡量標準。調整後淨虧損由普通股股東應佔淨虧損減去一次性衍生公允價值和增值費用確定。我們對調整後淨虧損的定義可能不能與其他公司使用的類似標題衡量標準的定義相比較。我們認為，這一非GAAP財務指標是對其報告的GAAP結果的補充，而不是替代它，通過提供更有針對性的經營業績指標，為投資者提供了有用的信息。這一指標被用作公司內部報告的一部分，以評估其運營和高級管理層的業績。
The following reconciliation calculates the adjusted loss per share:
以下對帳計算調整後的每股虧損：
|
3 months ended June 30, 2022 |
||||
| $ | ||||
Net loss attributable to common stockholders |
(5,024,389 | ) | ||
Add: |
||||
Provision for income taxes |
- | |||
Interest expense |
388,388 | |||
Depreciation expense |
1,488 | |||
EBITDA |
(4,634,512 | ) | ||
Add (Less) |
||||
Other (income) expense related to convertible note conversion |
50,908 | |||
Fair value change on derivative liabilities |
198,224 | |||
Adjusted EBITDA |
(4,385,381 | ) | ||
Weighted average number of common shares outstanding |
51,440,944 | |||
Adjusted Loss per Share, Basic and Diluted |
(0.085 | ) | ||
|
3個月 告一段落 2022年6月30日 |
||||
| $ | ||||
普通股股東應佔淨虧損 |
(5,024,389 | ) | ||
添加： |
||||
所得税撥備 |
- | |||
利息支出 |
388,388 | |||
折舊費用 |
1,488 | |||
EBITDA |
(4,634,512 | ) | ||
加(減) |
||||
與可轉換票據轉換相關的其他(收益)費用 |
50,908 | |||
衍生負債的公允價值變動 |
198,224 | |||
調整後的EBITDA |
(4,385,381 | ) | ||
已發行普通股加權平均數 |
51,440,944 | |||
調整後每股基本虧損和稀釋後每股虧損 |
(0.085 | ) | ||
Contacts:
聯繫人：
Investor Relations:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
investors@biotricity.com
投資者關係：
KCSA戰略傳播
瓦爾特·平託或傑克·珀金斯
(212) 896-1254
郵箱：Investors@Biotrity.com
Media Relations:
媒體關係：
Erica Fiorini, Russo Partners
(212) 845-4253
Erica.Fiorini@russopartnersllc.com
埃裏卡·菲奧里尼，Russo Partners
(212) 845-4253
郵箱：Erica.Fiorini@russopartnersllc.com
BIOTRICITY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS AT JUNE 30, 2022 (unaudited) AND MARCH 31, 2022 (audited)
(Expressed in US Dollars)
BIOTRICITY Inc.
簡明合併資產負債表
截至2022年6月30日(未經審計)和2022年3月31日(已審計)
(以美元表示)
| As at June 30, 2022 | As at March 31, 2022 | |||||||
| $ | $ | |||||||
CURRENT ASSETS |
||||||||
Cash |
7,207,974 | 12,066,929 | ||||||
Accounts receivable, net |
1,826,920 | 2,006,678 | ||||||
Inventory |
1,431,054 | 842,924 | ||||||
Deposits and other receivables |
380,592 | 406,280 | ||||||
Total current assets |
10,846,540 | 15,322,811 | ||||||
Deposits |
85,000 | 85,000 | ||||||
Long-term accounts receivable |
- | - | ||||||
Property and equipment |
25,970 | 27,459 | ||||||
Operating right-of-use lease asset [Note 10] |
1,192,169 | 1,242,700 | ||||||
TOTAL ASSETS |
12,149,679 | 16,677,970 | ||||||
CURRENT LIABILITIES |
||||||||
Accounts payable and accrued liabilities [Note 4]
|
2,701,077 | 2,595,747 | ||||||
Convertible promissory notes and short term loans [Note 5]
|
1,238,000 | 1,540,000 | ||||||
Derivative liabilities [Note 8] |
419,332 | 520,747 | ||||||
Operating lease liability [Note 10] |
219,033 | 210,320 | ||||||
Total current liabilities |
4,577,442 | 4,866,814 | ||||||
Federally guaranteed loans [Note 7] |
870,800 | 870,800 | ||||||
Term loan [Note 6] |
11,662,742 | 11,612,672 | ||||||
Derivative liabilities [Note 8] |
537,318 | 352,402 | ||||||
Operating lease liability [Note 10] |
1,061,795 | 1,120,018 | ||||||
TOTAL LIABILITIES |
18,710,097 | 18,822,706 | ||||||
STOCKHOLDERS' EQUITY (DEFICIENCY) |
||||||||
Preferred stock, $0.001 par value, 10,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 1 share issued and outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] |
1 | 1 | ||||||
Preferred stock, $0.001 par value, 20,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 6,872 and 7,201 preferred shares issued and outstanding as at June 30, 2022 and as at March 31, 2022, respectively [Note 9] |
8 | 7 | ||||||
Preferred stock |
1 | 1 | ||||||
Common stock, $0.001 par value, 125,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively. Issued and outstanding common shares: 50,219,034 and 49,810,322 as at June 30, 2022 and March 31, 2022, respectively, and exchangeable shares of 1,466,718 and 1,466,718 outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] |
51,685 | 51,277 | ||||||
Shares to be issued 95,515 and 123,817 shares of common stock as at June 30, 2022 and March 31, 2022, respectively) [Note 9] |
72,299 | 102,299 | ||||||
Additional paid-in-capital |
91,912,772 | 91,507,478 | ||||||
Accumulated other comprehensive loss |
(535,653 | ) | (768,656 | ) | ||||
Accumulated deficit |
(98,061,531 | ) | (93,037,142 | ) | ||||
Total stockholders' equity (deficiency) |
(6,560,418 | ) | (2,144,736 | ) | ||||
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY |
12,149,679 | 16,677,970 | ||||||
| 截至2022年6月30日 | 截至2022年3月31日 | |||||||
| $ | $ | |||||||
流動資產 |
||||||||
現金 |
7,207,974 | 12,066,929 | ||||||
應收賬款淨額 |
1,826,920 | 2,006,678 | ||||||
庫存 |
1,431,054 | 842,924 | ||||||
押金和其他應收款 |
380,592 | 406,280 | ||||||
流動資產總額 |
10,846,540 | 15,322,811 | ||||||
存款 |
85,000 | 85,000 | ||||||
長期應收賬款 |
- | - | ||||||
財產和設備 |
25,970 | 27,459 | ||||||
經營性使用權租賃資產[注10] |
1,192,169 | 1,242,700 | ||||||
總資產 |
12,149,679 | 16,677,970 | ||||||
流動負債 |
||||||||
應付賬款和應計負債[注4]
|
2,701,077 | 2,595,747 | ||||||
可轉換本票和短期貸款[注5]
|
1,238,000 | 1,540,000 | ||||||
衍生負債[注8] |
419,332 | 520,747 | ||||||
經營租賃負債[注10] |
219,033 | 210,320 | ||||||
流動負債總額 |
4,577,442 | 4,866,814 | ||||||
聯邦擔保貸款[注7] |
870,800 | 870,800 | ||||||
定期貸款[注6] |
11,662,742 | 11,612,672 | ||||||
衍生負債[注8] |
537,318 | 352,402 | ||||||
經營租賃負債[注10] |
1,061,795 | 1,120,018 | ||||||
總負債 |
18,710,097 | 18,822,706 | ||||||
股東權益(不足) |
||||||||
優先股，面值0.001美元，於2022年6月30日及2022年3月31日分別核準1,000,000股，分別於2022年6月30日及2022年3月31日發行及發行1股[注9] |
1 | 1 | ||||||
優先股，面值0.001美元，截至2022年6月30日和2022年3月31日分別為20,000股已發行優先股和已發行優先股分別為6,872股和7,201股[注9] |
8 | 7 | ||||||
優先股 |
1 | 1 | ||||||
普通股，面值0.001美元，截至2022年6月30日和2022年3月31日分別授權1.25億股。已發行和已發行普通股：截至2022年6月30日和2022年3月31日分別為50,219,034股和49,810,322股，截至2022年6月30日和2022年3月31日分別為1,466,718股和1,466,718股可交換股份[注9] |
51,685 | 51,277 | ||||||
於2022年6月30日及2022年3月31日分別發行95,515股及123,817股普通股)[注9] |
72,299 | 102,299 | ||||||
追加實收資本 |
91,912,772 | 91,507,478 | ||||||
累計其他綜合損失 |
(535,653 | ) | (768,656 | ) | ||||
累計赤字 |
(98,061,531 | ) | (93,037,142 | ) | ||||
股東權益合計(虧空) |
(6,560,418 | ) | (2,144,736 | ) | ||||
總負債與股東缺位 |
12,149,679 | 16,677,970 | ||||||
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE MONTHS ENDED JUNE 31, 2022 AND 2021 (unaudited)
(Expressed in US Dollars)
BIOTRICITY Inc.
簡明合併經營報表和全面虧損
截至2022年6月31日和2021年6月31日的三個月(未經審計)
(以美元表示)
|
3 Months Ended June 30, 2022 |
3 Months Ended June 30, 2021 |
|||||||
| $ | $ | |||||||
REVENUE |
2,056,052 | 1,764,110 | ||||||
Cost of Revenue |
830,923 | 525,426 | ||||||
GROSS PROFIT |
1,225,129 | 1,238,684 | ||||||
EXPENSES |
||||||||
General and administrative expenses [Notes 8, 9 and 10]
|
4,881,003 | 3,652,203 | ||||||
Research and development expenses |
821,176 | 588,997 | ||||||
TOTAL OPERATING EXPENSES |
5,702,179 | 4,241,200 | ||||||
Other (income)/expense [Note 8] [Note 9] |
- | (8,782 | ) | |||||
Loss upon convertible promissory notes conversion |
50,908 | 28,215 | ||||||
Accretion and amortization expenses [Note 5] [Note 6] |
50,070 | 2,335,167 | ||||||
Change in fair value of derivative liabilities [Note 8] |
198,224 | 298,983 | ||||||
NET LOSS BEFORE INCOME TAXES |
(4,776,252 | ) | (5,656,099 | ) | ||||
Income taxes |
- | - | ||||||
NET LOSS BEFORE DIVIDENDS |
(4,776,252 | ) | (5,656,099 | ) | ||||
Less: Preferred Stock Dividends |
248,137 | 241,264 | ||||||
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS |
(5,024,389 | ) | 5,897,363 | |||||
Translation adjustment |
233,003 | 6,560 | ||||||
COMPREHENSIVE LOSS |
(4,791,386 | ) | (5,890,803 | ) | ||||
LOSS PER SHARE, BASIC AND DILUTED |
(0.098 | ) | (0.151 | ) | ||||
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |
51,440,944 | 39,095,637 | ||||||
|
截至3個月 2022年6月30日 |
截至3個月 2021年6月30日 |
|||||||
| $ | $ | |||||||
收入 |
2,056,052 | 1,764,110 | ||||||
收入成本 |
830,923 | 525,426 | ||||||
毛利 |
1,225,129 | 1,238,684 | ||||||
費用 |
||||||||
一般和行政費用[附註8、9及10]
|
4,881,003 | 3,652,203 | ||||||
研發費用 |
821,176 | 588,997 | ||||||
總運營費用 |
5,702,179 | 4,241,200 | ||||||
其他(收入)/支出[注8][注9] |
- | (8,782 | ) | |||||
可轉換本票兑換損失 |
50,908 | 28,215 | ||||||
累加和攤銷費用[注5][注6] |
50,070 | 2,335,167 | ||||||
衍生負債的公允價值變動[注8] |
198,224 | 298,983 | ||||||
所得税前淨虧損 |
(4,776,252 | ) | (5,656,099 | ) | ||||
所得税 |
- | - | ||||||
派發股息前淨虧損 |
(4,776,252 | ) | (5,656,099 | ) | ||||
減去：優先股股息 |
248,137 | 241,264 | ||||||
普通股股東應佔淨虧損 |
(5,024,389 | ) | 5,897,363 | |||||
翻譯調整 |
233,003 | 6,560 | ||||||
綜合損失 |
(4,791,386 | ) | (5,890,803 | ) | ||||
每股基本虧損和稀釋後每股虧損 |
(0.098 | ) | (0.151 | ) | ||||
已發行普通股加權平均數 |
51,440,944 | 39,095,637 | ||||||
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)
(Expressed in US Dollars)
BIOTRICITY Inc.
簡明合併現金流量表
截至2022年6月30日和2021年6月30日的三個月(未經審計)
(以美元表示)
| Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | |||||||
| $ | $ | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES |
||||||||
Net loss |
(4,776,252 | ) | (5,656,099 | ) | ||||
Adjustments to reconcile net loss to net cash used in operations |
||||||||
Stock based compensation |
149,190 | 155,851 | ||||||
Issuance of shares for services |
7,051 | - | ||||||
Issuance of warrants for services |
77,414 | 151,897 | ||||||
Accretion and amortization expenses |
- | 2,335,167 | ||||||
Change in fair value of derivative liabilities |
198,224 | 298,983 | ||||||
Loss on debt |
50,908 | 28,213 | ||||||
Property, plant and equipment depreciation |
1,488 | - | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable, net |
179,758 | (401,818 | ) | |||||
Inventory |
(588,130 | ) | 92,694 | |||||
Deposits and other receivables |
(4,312 | ) | (86,221 | ) | ||||
Accounts payable and accrued liabilities |
416,047 | 399,937 | ||||||
Net cash used in operating activities |
(4,288,164 | ) | (2,681,396 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES |
||||||||
property, plant and equipment |
- | - | ||||||
Net cash used in investing activities |
- | - | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES |
||||||||
Issuance of common shares, net |
- | - | ||||||
Issuance of preferred shares, net |
- | - | ||||||
Redemption of preferred shares |
(328,904 | ) | - | |||||
Exercise of warrants for cash |
- | 146,250 | ||||||
Federally guaranteed loans |
- | 499,900 | ||||||
Proceeds from (repayment to) convertible notes, net |
- | - | ||||||
Proceeds from (repayment to) convertible debentures, net |
- | 139,780 | ||||||
Issuance of shares from uplisting |
- | - | ||||||
Proceeds pursuant to term loan, net |
50,070 | - | ||||||
Preferred Stock Dividend |
(516,817 | ) | (204,842 | ) | ||||
Net cash provided by financing activities |
(795,651 | ) | 581,088 | |||||
Effect of foreign currency translation |
224,860 | 100,334 | ||||||
Net increase (decrease) in cash during the period |
(5,083,815 | ) | (1,999,974 | ) | ||||
Cash, beginning of period |
12,066,929 | 2,201,562 | ||||||
Cash, end of period |
7,207,974 | 201,588 | ||||||
| 截至2022年6月30日的三個月 | 截至2021年6月30日的三個月 | |||||||
| $ | $ | |||||||
經營活動的現金流 |
||||||||
淨虧損 |
(4,776,252 | ) | (5,656,099 | ) | ||||
調整以調節淨虧損與運營中使用的淨現金 |
||||||||
基於股票的薪酬 |
149,190 | 155,851 | ||||||
為服務而發行股份 |
7,051 | - | ||||||
為服務發行認股權證 |
77,414 | 151,897 | ||||||
累加和攤銷費用 |
- | 2,335,167 | ||||||
衍生負債的公允價值變動 |
198,224 | 298,983 | ||||||
債務損失 |
50,908 | 28,213 | ||||||
財產、廠房和設備折舊 |
1,488 | - | ||||||
經營性資產和負債變動情況： |
||||||||
應收賬款淨額 |
179,758 | (401,818 | ) | |||||
庫存 |
(588,130 | ) | 92,694 | |||||
押金和其他應收款 |
(4,312 | ) | (86,221 | ) | ||||
應付賬款和應計負債 |
416,047 | 399,937 | ||||||
用於經營活動的現金淨額 |
(4,288,164 | ) | (2,681,396 | ) | ||||
投資活動產生的現金流 |
||||||||
財產、廠房和設備 |
- | - | ||||||
用於投資活動的現金淨額 |
- | - | ||||||
融資活動產生的現金流 |
||||||||
普通股發行，淨額 |
- | - | ||||||
發行優先股，淨額 |
- | - | ||||||
優先股的贖回 |
(328,904 | ) | - | |||||
行使現金認股權證 |
- | 146,250 | ||||||
聯邦擔保貸款 |
- | 499,900 | ||||||
可轉換票據收益(償還)，淨額 |
- | - | ||||||
可轉換債券收益(償還)，淨額 |
- | 139,780 | ||||||
通過上市發行股票 |
- | - | ||||||
根據定期貸款獲得的收益，淨額 |
50,070 | - | ||||||
優先股分紅 |
(516,817 | ) | (204,842 | ) | ||||
融資活動提供的現金淨額 |
(795,651 | ) | 581,088 | |||||
外幣折算的影響 |
224,860 | 100,334 | ||||||
期內現金淨增(減)額 |
(5,083,815 | ) | (1,999,974 | ) | ||||
期初現金 |
12,066,929 | 2,201,562 | ||||||
期末現金 |
7,207,974 | 201,588 | ||||||
SOURCE: Biotricity, Inc.
資料來源：Biotricity，Inc.